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88 The Journal of Thoracic and Cardioackground: An important component of matrix remodeling during thoracic aortic
neurysm progression is the balance between matrix metalloproteinases and their
ndogenous inhibitors (tissue inhibitors of metalloproteinases). However, whether and
o what degree matrix metalloproteinase/tissue inhibitor of metalloproteinases profiles
hange over time with an evolving thoracic aortic aneurysm remains unclear.
ethods: Descending thoracic aortic aneurysms were induced in mice (FVB strain,
5 minutes of 0.5 mol/L CaCl2 exposure) and followed for 24 hours, 72 hours,
week, 2 weeks, 4 weeks, or 8 weeks (each group, n  13). Thoracic aortic aneurysm
ize was determined by means of video micrometry, and immunoblotting was used to
easure aortic matrix metalloproteinase 2, 8, 9, and 12 and tissue inhibitor of metal-
oproteinases 1 and 4 levels (expressed as a percentage of control values, n  13).
esults: Increased aortic diameter was detected by 72 hours and reached a maximal
ize at 4 weeks (135%  4% increase from baseline, P  .05), which is consistent
ith thoracic aortic aneurysm progression. Active matrix metalloproteinase 8 (col-
agenase) levels increased at 72 hours (178%  49%, P  .05 from control), and
ctive matrix metalloproteinase 12 (elastase) levels increased by 24 hours (138% 
1%, P  .05), whereas active matrix metalloproteinase 2 levels increased at
2 hours and 1 week after thoracic aortic aneurysm induction (72 hours: 158% 
2%, 1 week: 162%  19%; P  .05). At 1 week after thoracic aortic aneurysm
nduction, active matrix metalloproteinase 9 and 12 levels decrease (matrix metal-
oproteinase 9: 55%  5%; matrix metalloproteinase 12: 63%  5%; P  .05);
owever, matrix metalloproteinase 9 and 12 levels were increased from these values
t 4 and 8 weeks (P  .05). Tissue inhibitor of metalloproteinases 1 levels were
ecreased at 1 week (52% 15%, P .05) and later returned to control values, whereas
issue inhibitor of metalloproteinases 4 levels increased at the late thoracic aortic
neurysm time points (4 weeks: 278%  46%; 8 weeks: 213%  40%; P  .05).
onclusions: These findings show 2 phases of matrix metalloproteinase abundance
uring murine thoracic aortic aneurysm formation. The late tissue inhibitor of
etalloproteinases 4 increase might explain prevention of further aortic dilation past
weeks. Unique matrix metalloproteinase/tissue inhibitor of metalloproteinases
emporal relationships occurred during the natural history of thoracic aortic aneu-
ysm progression that might hold both diagnostic and therapeutic relevance.
horacic aortic aneurysms (TAAs) represent a serious and potentially lethal
disease with high mortality and morbidity rates. TAA formation and pro-
gression is a multifactorial process that involves both cellular and extracel-
ular processes.1,2 Ascending and descending TAAs likely differ in cause 
atural progression,3 and anatomic and cellular differences between the ascending
vascular Surgery ● October 2006
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A
CDnd descending aorta might explain why TAAs that develop
n these areas differ. With respect to the extracellular matrix
ECM), degradation and remodeling universally occurs with
escending TAAs, but the underlying mechanisms remain
oorly understood.
ECM degradation in aneurysm tissue is caused in part by
family of endopeptidases termed matrix metalloprotein-
ses (MMPs).4,5 Several members of the MMP family h
een implicated in the pathogenesis of aortic aneurysms,
ncluding gelatinase A (MMP-2), gelatinase B (MMP-9),
nd macrophage elastase (MMP-12).6-9 The major struc-
ural component that lends strength to the aortic wall is
lastin. Elastin fiber fragmentation is a frequent histologic
nding in aneurysmal tissue.10 MMP-12, released from
acrophages, has the ability to directly degrade elastin
ithin the aortic wall, facilitating aneurysmal dilatation
ith the loss of structural integrity. Neutrophil collagenase
MMP-8) and MMP-9 are released in their preformed states
rom neutrophils in the early stages of inflammation. In addi-
ion, it has been established that the endogenous tissue inhib-
tors of the MMPs (TIMPs) play a role in the modulation of
MP activity.11,12 Radiolabeled MMP inhibitors, combine
ith in vivo scintigrapghy in experimental animal models,
ave opened the door for noninvasive clinical diagnostic meth-
ds in MMP-related diseases.13 Although previous studie
ave demonstrated clear roles for these specific MMPs and
IMPs in aneurysmal disease, no study to date has determined
he relative changes in abundance over the course of aneurys-
al development. We hypothesized that in a model of de-
cending TAA,14 temporal changes in these critical MMP 
IMP types occur throughout TAA progression. Hence the
resent study examines the changes in these species after
xperimental descending TAA induction.
ethods
xperimental Design
nimals used in the study were adult wild-type FVB mice (n 
1). Equal numbers of male (n  47, 52%) and female (n  44,
8%; P  .54) mice were used, and all mice were between 8 and
2 weeks of age at the time of the initial operation. Mice were
andomly assigned to one of 6 groups for terminal harvest and
nalysis 24 hours (n  13), 72 hours (n  13), 1 week (n  13),
weeks (n  13), 4 weeks (n  13), or 8 weeks (n  13) after the
nitial operation. From each group, the aortas from 3 mice were
ormaldehyde fixed for histologic studies, and the aortas from 10
Abbreviations and Acronyms
ECM  extracellular matrix
MMP matrix metalloproteinase
TAA  thoracic aortic aneurysm
TIMP tissue inhibitor of metalloproteinasesice were frozen for biochemical analysis. One mouse each from f
The Journal of Thoraciche 24-hour and 1-week groups were excluded because of inade-
uate tissue. For biochemical analysis, the above animals were
ompared with age-matched, control unoperated animals (n 10).
ll animals were treated and cared for in accordance with the
ational Institutes of Health “Guide for the Care and Use of
aboratory Animals” (National Research Council, Washington,
C, 1996), and the protocols were approved by the Medical
niversity of South Carolina Institutional Animal Care and Use
ommittee (protocol no. 2146).
perative Procedure
urine TAA production was induced as previously described.12,15
riefly, periadventitial calcium chloride (CaCl2), which has been
hown to lead to structural disruption of the medial layer of the
ortic wall and the induction of a localized inflammatory response,
as applied to the abluminal surface of the descending thoracic
orta to induce aneurysmal dilatation.14 This experimental mode
f aortic aneurysm was selected for this study, as opposed to the
lastase perfusion model, because the modest dilation it produces
ikely mimics the early stages of aneurysmal formation.
Anesthetized and orotracheally intubated animals were sub-
ected to fifth intercostal space thoracotomy with exposure of the
escending thoracic aorta. Aortic diameter measurements were
btained. A sponge soaked in 0.5 mol/L CaCl2 was placed on the
istal half of the descending thoracic aorta for 15 minutes. After
5 minutes, the sponge was removed, the chest was irrigated, and
he lung was re-expanded. The operative mortality rate was 20%.
he mice then survived for the time points indicated before ter-
inal study and aortic harvest.
ortic Diameter Measurements
ortic diameter, as assessed by means of video micrometry, was
easured for each mouse at both the baseline and predetermined
ime point terminal operation. Digital images of the descending
horacic aorta were obtained by using a color CCD camera (KP
Z0B, Hitachi Kokusai Electric Inc, Tokyo, Japan) linked to a
aptop computer with digital imaging software (WinTV2000,
auppauge Computer Works, Inc, Hauppage, NY). Aortic diam-
ter measurements were made through a digital video caliper
DMZR, Techni-Quip, Polk City, Fla). Terminal aortic size was
xpressed as a percentage increase from respective baseline
easurement.
ortic Harvest
ith the animal anesthetized, the left thoracotomy was reopened
nd extended beneath the xiphoid process. Terminal aortic diam-
ter measurements were obtained in vivo before death to ensure
hat the aorta was sufficiently pressurized. The aorta was then
arefully harvested from its root to the aortic bifurcation. The
escending thoracic portion was then divided from the ascending
orta, as well as the abdominal aorta.
MP and TIMP Abundance
or this study, the relative abundances of MMPs/TIMPs were exam-
ned by using quantitative immunoblotting techniques, which have
een described in detail previously.16 Briefly, 10 g of aorta extra
as loaded onto a 4% to 12% Bis-Tris gradient gel and subjected toractionation by means of electrophoresis. The fractionated proteins
and Cardiovascular Surgery ● Volume 132, Number 4 789
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CDere transferred to nitrocellulose membranes (0.45 m, Bio-Rad) and
ncubated in antiserum (0.4 g/mL in 5% nonfat dry milk/phosphate-
uffered saline) specifically corresponding to MMP-8 (PC493, On-
ogene), MMP-2 (AB19015, Chemicon, Temecula, Calif), MMP-9
AB804, Chemicon), and MMP-12 (AB19051, Chemicon). Because
MPs exist in both a latent and active form, the molecular weight
ands corresponding to each were quantified. Positive controls (re-
ombinant enzyme) were included in the immunoblotting approach.
he TIMPs were measured in identical fashion by using specific
ntisera for TIMP-1 (AB770, Chemicon) and TIMP-4 (AB816,
hemicon). A secondary peroxidase-conjugated antibody was then
pplied (1:5000, 5% nonfat dry milk/phosphate-buffered saline), and
ignals were detected with a chemiluminescent substrate (Western
ightning Chemiluminescence Reagent Plus, Perkin Elmer, Norwalk,
onn). The film was developed in a Konica SRX-101A medical film
rocessor and analyzed with Gel-Pro Analyzer software (version
.1.14, Media Cybernetics Inc, Silver Spring, Md).17
tatistical Analysis
ll statistical procedures were performed with the Stata statistical
oftware package (Stata Corp, College Station, Tex). Terminal
ortic diameter measurements were analyzed by using the Wil-
oxon matched-pairs test to determine differences from baseline
alues. Comparisons of aortic diameter between groups were made
ith Mann-Whitney U tests to determine statistical differences.
MP immunoblotting data were analyzed by using Kruskal-
allis analysis of ranks and then subjected to Mann-Whitney U
ests to determine differences between groups. Data are presented
s means  standard error of the means.
esults
ortic diameter increased by 72 hours, which is consistent
ith TAA formation and reached a maximal size at 4 weeks
fter CaCl2 exposure (Figure 1).
Levels of the latent form of MMP-8 (85 kd) decreased
rom control levels at 72 hours (78%  11%, P  .06) and
eached lowest relative abundance at 1 week after TAA
nduction operations (44%  6%, P  .05). In contrast,
ctive MMP-8 (58 kd) levels were increased at 72 hours
Figure 2, A) and returned to control values by 1 week
Latent MMP-12 (54 kd) levels were increased from
ontrol levels at 72 hours (115% 6%, P .05) after TAA
nduction. Latent MMP-12 levels were decreased from con-
rol levels, however, at 1 week (81%  5%, P  .05) and
eturned to control levels at 2 weeks and beyond. Active
MP-12 (45 kd) levels were increased at 24 hours and
ecreased at 1 week before returning to control levels at
 weeks (Figure 2, B).
Latent MMP-2 (72 kd) levels demonstrated no change at
ny time point in this study. In contrast, active MMP-2
62 kd) levels increased significantly at 72 hours and 1 week
fter TAA induction operations (Figure 3, A) and then
eturned to control values at 2 weeks and beyond. Latent
MP-9 (92 kd) levels reached their greatest abundance at
2 hours after TAA operations (268% 49%, P .05) and
ecreased from control levels at 2 weeks (79%  7%, P  T
90 The Journal of Thoracic and Cardiovascular Surgery ● Octo05). Active MMP-9 (88 kd) levels were significantly de-
reased at 1 week and increased to control levels at 2 weeks
Figure 3, B). At 8 weeks, active MMP-9 levels w
aximally increased compared with levels seen at the other
ime points in this study.
TIMP-1 levels decreased from control levels at 1 week
Figure 4, A) and then returned to control levels therea
IMP-4 levels were not changed at the early time points in
his study; notably, however, at 4 weeks, TIMP-4 levels
ere increased to almost 300% of unoperated control values
nd remained increased at 8 weeks (Figure 4, B).
iscussion
ortic aneurysmal disease is characterized by structural
lterations of the aortic wall resulting from the degradation
f ECM components. These changes are associated with an
nflammatory infiltrate and altered production of MMPs,
hich mediate the degradation of ECM proteins.5,8,9 This
tudy was designed to follow the active forms of major
MP types from representative classes of proteases impli-
ated in TAA formation (MMP-2, MMP-8, MMP-9, and
MP-12), as well as their endogenous tissue inhibitors
TIMP-1 and TIMP-4), throughout the course of TAA pro-
ression in a reproducible murine model. These results
emonstrated a distinctive biphasic profile of MMP and
igure 1. Change in aortic diameter between baseline and ter-
inal values, as measured by means of video micrometry. There
as no change in aortic size at 24 hours; however, all time points
2 hours and beyond demonstrated statistical increase in size
rom baseline. Aortic size reached its greatest value at 4 weeks
fter thoracic aortic aneurysm (TAA) operations. *P < .05 from
ontrol, #P< .05 from 24 hours,P< .05 from 72 hours, P< .05
rom 1 week, P < .05 from 2 weeks.IMP abundance over the 8-week study period. Specifi-
ber 2006
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A
CDally, this model demonstrated an early phase of aneurysmal
xpansion characterized by relative increases in MMP abun-
ance, supporting an increase in proteolysis. A later phase
emonstrated an increase in the relative abundance of
IMPs supporting decreased proteolysis. These temporal
hanges in MMP/TIMP relationships likely play a mecha-
istic role in the matrix-remodeling characteristic of TAAs.
arly-phase Responses (24 Hours–1 Week)
esults from this study have shown increases in MMP-8,
MP-12, and MMP-2 levels accompanied by a decrease in
IMP-1 levels during the early phase of aneurysm induc-
ion. These data imply a change in the ratio of MMPs to
IMPs, favoring a state of proteolysis, which is consistent
ith the initiation of aortic dilation and the beginning ofneurysm formation. s
The Journal of ThoracicMMP-8 is highly expressed within circulating neutrophils
nd comprises the major neutrophil collagenase, showing 20-
old specificity for fibrillar type I collagen compared with type
II collagen or the nonfibrillar type IV collagen.18,19 Given the
bundance of type I collagen in the aorta, MMP-8 has been
mplicated in aneurysmal collagen degradation.20 MMP-8 has
lso been linked to aneurysmal disease as a marker for neu-
rophil infiltration into the aneurysmal wall.21 This report is th
rst to demonstrate the presence of active MMP-8 in the
eveloping TAA, as well as the first to demonstrate a unique
emporal induction, showing an immediate increase in active
MP-8. Latent MMP-8 levels showed reciprocal changes
onsistent with release of preformed latent MMP-8 stores and
onversion to the active form, with little additional de novo
Figure 2. A, The representative immunoblot dem-
onstrates the 58-kd band characteristic of active
matrix metalloproteinase (MMP) 8. MMP-8 showed
early increased abundance, which peaked at 72
hours after the operation; however, MMP-8 levels
were found to be near control values by 1 week
and remained near control values at all other time
points in this study. *P < .05 from control, P <
.05 from 72 hours. B, The representative immuno-
blot demonstrates the 45-kd band characteristic of
active MMP-12. MMP-12 levels were increased
early and increased from control values at 24
hours. After this initial spike, MMP-12 levels were
decreased in abundance at 1 week and returned to
normal at 2 weeks. *P < .05 from control, #P < .05
from 24 hours, P < .05 from 72 hours, P < .05
from 1 week, P < .05 from 2 weeks. TAA, Tho-
racic aortic aneurysm.ynthesis. In light of the fact that MMP-8 is primarily synthe-
and Cardiovascular Surgery ● Volume 132, Number 4 791
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CDized and released by inflammatory cells, the crescendo of
MP-8 release observed early in this model of TAA is likely
eflective of an inherent inflammatory response.
Levels of MMP-12, or macrophage elastase, have been
ound to be consistently increased in human aortic aneu-
ysmal tissue when compared with that seen in control
ortas.22 Furthermore, it has been implicated as the m
ontributor to elastin degradation in aneurysmal tissu9
n this study active MMP-12 levels were significantly
ncreased over baseline values by 24 hours and then
ecreased to less than baseline values by 1 week. This
arly-phase response is consistent with macrophage in-
ltration induced by the surgical procedure. In addition,
parallel biphasic response in latent MMP-12 was ob-
erved, which is consistent with both preformed proen-
yme release and de novo proenzyme synthesis. m
92 The Journal of Thoracic and Cardiovascular Surgery ● OctoMMP-2, predominantly expressed by smooth muscle
ells and fibroblasts of mesenchymal origin, has long been
mplicated in the development of abdominal and thoracic
neurysms, both in human subjects and in experimental
ouse models.6,23 Interestingly, in the current study acti
MP-2 levels were found to be increased during the early
hase of aneurysm development, peaking at 1 week after
nduction operations and then decreasing rapidly to baseline
alues at subsequent time points. Reciprocal changes were
bserved over time with latent MMP-2, which is consistent
ith early release of latent MMP-2 and rapid conversion to
he active form. The activation of MMP-2 is a coordinated
nd localized cellular event requiring the interaction of
everal molecules and proteolytic steps.24 Thus changes in
ny of these steps or depletion of mesenchymal cell content
Figure 3. A, The representative immunoblot
shows the 62-kd band of active matrix metallopro-
teinase (MMP) 2. MMP-2 levels increased from
control values at 72 hours and peaked in abun-
dance at 1 week after the operation. MMP-2 levels
then decreased to near control values at 2 weeks
and at all time points afterward. *P < .05 from
control, P < .05 from 72 hours, P < .05 from 1
week. B, The representative immunoblot shown in
this figure shows the 88-kd band of active MMP-9.
MMP-9 levels were decreased at 1 week; how-
ever, levels returned to control values at 2 weeks.
MMP-9 levels were maximally increased at 8
weeks, although this increase was not significant
from control values. *P< .05 from control, #P< .05
from 24 hours, P < .05 from 72 hours, P < .05
from 1 week. TAA, Thoracic aortic aneurysm.ight have led to attenuation of MMP-2 activational states.
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A
CDate-phase Responses (2-8 Weeks)
he present study showed increases in active MMP-12
nd active MMP-9 levels, as well as TIMP-4 levels,
uring the late phase of aneurysm formation. This was
ccompanied by continued aneurysm expansion through
weeks, followed by attenuation and plateau between 4
eeks and 8 weeks.
Active MMP-12 levels, which displayed an early re-
ponse that was suppressed by 1 week, rebounded, reaching
ontrol levels by 2 weeks and peaked a second time at
weeks, before returning to baseline at 8 weeks. Because
he early response was likely due to an acute inflammatory
nfiltrate, the second rebound response likely represents a
hift from an acute inflammatory reaction to a more chronic
eaction. Previous studies have shown chronic inflammation
nd elastin degradation in abdominal aneurysms.25 More-
ver, elastin degradation products have been shown to have A
The Journal of Thoracichemotactic properties for monocytes and macrophages26
hich might explain the rebound in active MMP-12 abun-
ance observed during the late-phase response.
Several studies in human and experimental animal
ystems have demonstrated a role for MMP-9 in aneu-
ysmal disease and have identified MMP-9 as the most
bundant gelatinolytic MMP in aneurysm tissue.8,27 In-
ltrating macrophages are the primary source of MMP-9
ecause mesenchymal cells do not normally produce
MP-9. Induction of experimental abdominal aortic an-
urysms in MMP-9/ animals have demonstrated di-
inished elastin degradation and suppression of aneu-
ysm formation.28,29 In this study active MMP-9 lev
ere decreased from reference control levels at 1 week
nd returned to control levels by 2 weeks, reaching the
ost increased values at 8 weeks after TAA induction.
Figure 4. A, The representative immunoblot shows
the 22-kd band of tissue inhibitor of metalloprotein-
ases (TIMP) 1. TIMP-1 levels were found to be max-
imally decreased at 1 week before returning to con-
trol values at 2 weeks and beyond. *P < .05 from
control, #P < .05 from 24 hours, P < .05 from 72
hours, P < .05 from 1 week. B, The representative
immunoblot shows the 28-kd band characteristic of
TIMP-4. TIMP-4 levels were not changed from con-
trol values until 4 weeks, when levels were mark-
edly increased from control values and remained
increased at 8 weeks. *P < .05 from control, #P <
.05 from 24 hours, P < .05 from 72 hours, P <
.05 from 1 week, P < .05 from 2 weeks. TAA,
Thoracic aortic aneurysm.lthough active MMP-9 levels were not increased until
and Cardiovascular Surgery ● Volume 132, Number 4 793
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A
CDate in this study, latent MMP-9 levels were increased
uring the early time period (24 hours). These results
ight suggest that the role of MMP-9 in aneurysmal
isease is in some measure related to alternative mecha-
isms other than through direct proteolysis.
The principle regulatory mechanism attenuating MMP
ctivity in vivo is mediated through noncovalent interac-
ions with a family of endogenous inhibitors or TIMPs.
IMP-1 and TIMP-4 are the predominant TIMP species
xpressed in the aortic vasculature. From previous stud-
es, experimental aneurysm induction in TIMP-1/ mice
as shown increased aortic dilation.11,12 The present
tudy is the first study to examine TIMP-4 in relation to
ortic dilation and aneurysm formation. In this study a
rogressive loss of TIMP-1 was observed over the first
eek after surgical induction of TAA, followed by a
eturn of TIMP-1 protein levels to baseline values. Inter-
stingly, TIMP-4 levels were found to be markedly in-
reased at 4 and 8 weeks after aneurysm induction oper-
tions. The 3-fold increase in TIMP-4 levels coincided
ith a relative decrease in the rate of aneurysmal expan-
ion. This plateau in aortic dilation might represent a
toichiometric MMP/TIMP shift from an overall proteo-
ytic state to a more homeostatic one.
imitations and Summary
he goal of the current study was to assess MMP and
IMP abundance over the time course of aneurysm in-
uction and formation in a periadventitial calcium chlo-
ide murine model of TAA. This study, however, is not
ithout some limitations. First, the inflammatory nature
f this model might limit its applicability to the TAAs in
he ascending aorta, which in general tend to have less of
n inflammatory component. Second, MMP abundance in
his study was assessed by using antibodies directed
gainst the latent and active forms of each MMP and
omparing the determined levels at each time point with
hat of an unoperated control. Because of the limitations
nherent in immunoblotting, comparisons between MMPs
r TIMPs cannot be made directly. Third, the mouse
orta provides a small amount of tissue for biochemical
nalysis, and the immunoblotting techniques used in this
xperiment were therefore only directed at a small subset
f the proteases and inhibitors known to play a role in
ascular disease. Because neither TIMP-2, which plays a
ole in both the activation and inhibition of MMP-2, nor
IMP-3, which is known to interact with MMP-9, were
nalyzed, additional studies concerning these proteins
ight add additional insight. Lastly, as with any exper-
mental animal model, this murine model of TAA is
onducted in a separate species, and extrapolation to
uman TAAs must be done with caution.
94 The Journal of Thoracic and Cardiovascular Surgery ● OctoNevertheless, these findings show 2 phases of MMP
bundance throughout the course of murine TAA formation.
nique MMP and TIMP temporal relationships were ob-
erved during TAA progression, which might hold both
uture diagnostic and therapeutic relevance.
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